Device PIPEs Flush with Opportunity

A review of private investments in publicly traded medical device companies in 2008.

Venture capitalists really have little choice but to consider making private investments in public equities a part of their regular diet. Prices for public equities are too low to ignore, and VCs clearly need to keep a portion of their capital invested in more liquid public equities. No doubt, public equities will provide them a clearer path toward paying out distributions to limited partners once the general partners set out to raise a new fund.

The public markets clearly remain a long-term investment, which suits the appetite of venture capitalists just fine. A review of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.